AZD9291, an EGFR-TKI, for T790M-mediated resistance in non-small cell lung cancer - European Medical Journal

AZD9291, an EGFR-TKI, for T790M-mediated resistance in non-small cell lung cancer

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the clinical development of AZD9291, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of patients with EGFR T790M-mutant non-small cell lung cancer (NSCLC) following resistance to frontline anti-EGFR therapy.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given